Having a large clinical trial portfolio means giving patients treatment options often not available anywhere else, and years before they become the standard of care. To learn more about Karmanos Cancer Institute clinical trials or to see if a trial is right for you, please call 1-800-KARMANOS (1-800-527-6266) or request an appointment below
  • A Phase I Study of the Combination of a Selective Inhibitor of Nuclear Export (SINE), Selinexor with Carfilzomib and Dexamethasone in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma.

    Cancer Categories
    • Hematologic (Blood Cancers)
    Karmanos Trial ID
    • 2014-090
    NCT ID
    • NCT02199665
    Age Group
    • Adult
    • National
    PhaseClick for Clinical Trial Phase DefinitionPhase I
    Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
    • Phase I
    Principal Investigator
    • Jeffrey
      Zonder, M.D.

      Oncology - Hematology, Oncology - Medical View Profile


    Determine the maximum tolerated dose (MTD) and the recommended phase II dose (RP2D) of the combination of Selinexor, Carfilzomib, and Dexamethasone in relapsed and relapsed/refractory multiple myeloma
    1. Determine safety and tolerability
    2. Determine the efficacy, as measured by the rates of stable disease or better (including minimal response, partial response, very good partial response, complete response, and stringent complete response)
    3. To perform pharmacokinetic studies at first cycle for each dose level for both Selinexor and Carfilzomib, and compare the results to those from their respective single arm trials. This will allow us to establish whether the plasma concentration and metabolism of each drug is altered when administered in combination.
  • Locations


    Karmanos Cancer Institute - Detroit Headquarters

    4100 John R
    Detroit, MI 48201
    Get Directions
    Phone: 800-527-6266